[Form 3] COMPUGEN LTD Initial Statement of Beneficial Ownership
Compugen Ltd filed an initial Form 3 for Zurit Levine, SVP, Business Development, detailing existing equity holdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Compugen Ltd filed an initial Form 3 for Zurit Levine, SVP, Business Development, detailing existing equity holdings. Levine directly holds 29,375 Ordinary Shares, including 25,821 restricted stock units that vest in staged quarterly installments. She also holds multiple share options over Ordinary Shares with exercise prices between 0.8292 and 14.4000, expiring from 2026 through 2035. These entries reflect current positions, not new market purchases or sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (7)
- F1. Includes 25,821 restricted stock units ("RSUs"). 7,821 RSUs vest in 11 equal quarterly installments commencing on March 31, 2026; and 18,000 RSUs vest 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- F2. Fully vested.
- F3. This option vested 25% on March 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- F4. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- F5. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- F6. This option vested 25% on September 30, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- F7. This option vests 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
